Welcome to our dedicated page for Harrow Health SEC filings (Ticker: HROW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harrow, Inc. filings document an ophthalmic pharmaceutical business built around branded products and ImprimisRx, including operating results, stockholder communications and Regulation FD presentations tied to its U.S. commercialization strategy. Current reports disclose material events such as product and business updates, executive appointments and compensation arrangements, the completed Melt Pharmaceuticals acquisition, and capital-structure matters involving senior unsecured notes due 2030.
Proxy materials cover shareholder voting matters, board governance and executive compensation. The filing record also includes disclosures on material agreements, risk-related cautionary statements, and clinical or regulatory topics connected to Harrow's ophthalmic product portfolio.
Sternberg Perry J. reported acquisition or exercise transactions in this Form 4 filing.
Harrow, Inc. director Perry J. Sternberg reported receiving a grant of 5,248 restricted stock units as compensation for services. These RSUs vest in equal quarterly installments over one year from the grant date, with the underlying common shares delivered only after his service with the company ends.
SILVERNAIL LAUREN P reported acquisition or exercise transactions in this Form 4 filing.
Harrow, Inc. director Lauren P. Silvernail received a grant of 5,248 restricted stock units as equity compensation for services. These RSUs vest in equal quarterly installments over one year from the grant date, and the underlying shares will not be delivered, transferred, or sold until service terminates.
Graves Adrienne L reported acquisition or exercise transactions in this Form 4 filing.
Harrow, Inc. director Adrienne L. Graves received a grant of 5,248 Restricted Stock Units as compensation for services. These RSUs vest in equal quarterly installments over one year from the grant date, and the underlying shares will be delivered only upon termination of service and cannot be transferred or sold before then.
Harrow, Inc. reported the results of its 2026 annual stockholder meeting. A total of 37,273,420 shares were entitled to vote, and 29,830,973 shares were present or represented by proxy. All four director nominees were elected to serve until the 2027 annual meeting. Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers and ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Harrow, Inc. furnished a corporate presentation as an exhibit to a current report. The presentation, dated June 2026, may be used by management at investor conferences and meetings with analysts and other interested parties. The material is provided under Regulation FD as supplemental information.
The company states that the presentation and related disclosure are furnished rather than filed, which means they are not subject to certain liability provisions and are not automatically incorporated into other securities filings unless specifically referenced.
Harrow, Inc. director Adrienne L. Graves bought 1,000 shares of common stock in an open-market transaction at $31.07 per share. This purchase on May 18, 2026 brings her directly held stake to 1,000 shares, indicating a new personal equity position in the company.
Harrow, Inc. director Lauren P. Silvernail purchased 1,000 shares of Harrow common stock in an open-market transaction at $31.00 per share. Following this transaction, Silvernail directly owns 1,000 common shares, indicating this filing reflects an initial reported stake rather than a large position change.
Shojaei Amir reported acquisition or exercise transactions in this Form 4 filing.
Harrow, Inc. reported that Chief Scientific Officer Amir Shojaei received a grant of 10,000 restricted stock units, each representing a right to one share of common stock. These RSUs vest in full on May 15, 2029, contingent on his continued service, and reflect compensation rather than open-market trading.
Harrow, Inc.'s Chief Executive Officer Mark L. Baum reported an open-market purchase of 10,000 shares of common stock at a weighted average price of $30.20 per share. After this transaction, he directly owns 2,996,130 shares. The filing notes the shares were bought in multiple trades between $30.18 and $30.34 per share.
Harrow, Inc.’s president and CFO, Andrew R. Boll, bought additional company stock. On May 14, 2026, he made open-market purchases totaling 3,500 shares of Harrow common stock at a price of $29.90 per share. After these transactions, he directly owns 814,679 Harrow common shares.
The filing notes the 3,500 shares reflect two separate open-market trades on that date, each executed at $29.90 per share, and indicates that detailed trade information is available upon request.